I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Treatment of MRSA pneumonia: Clinical and economic comparis..:
Wilke, Michael H
;
Becker, Karsten
;
Kloss, Sebastian
...
http://www.egms.de/static/en/journals/id/2017-5/id000028.shtml. , 2017
Link:
https://doi.org/10.3205/id000028
RT Journal T1
Treatment of MRSA pneumonia: Clinical and economic comparison of linezolid vs. vancomycin – a retrospective analysis of medical charts and re-imbursement data of real-life patient populations
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:85e85f9f778943afa04450f2416577e4&Exemplar=1&LAN=DE A1 Wilke, Michael H A1 Becker, Karsten A1 Kloss, Sebastian A1 Heimann, Sebastian M A1 Goldmann, Anton A1 Weber, Bertram A1 Pletz, Mathias W A1 Simon, Philipp A1 Petrik, Christian PB German Medical Science GMS Publishing House YR 2017 K1 linezolid K1 vancomycin K1 methicillin resistant Staphylococcus aureus K1 pneumonia K1 treatment outcome K1 cost-benefit analysis K1 Zyvox® K1 Pfizer K1 Infectious and parasitic diseases K1 RC109-216 JF http://www.egms.de/static/en/journals/id/2017-5/id000028.shtml LK http://dx.doi.org/https://doi.org/10.3205/id000028 DO https://doi.org/10.3205/id000028 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)